BioDrone Therapeutics

BioDrone Therapeutics is a U.S. biotech company established in 2019 in Seattle to support the global business development and commercialization of the BioDrone platform originally developed by MDimune. The company focuses on a cell-derived vesicle drug delivery platform designed to selectively deliver therapeutic payloads, including RNA cargos and small molecules, to target tissues. Its business model emphasizes partnerships and open innovation, integrating external technologies into the BioDrone platform for applications across oncology, rare disease, CNS, and other areas. Publicly available information suggests the company is primarily a platform and collaboration vehicle rather than a standalone late-stage product company. Its activities appear to remain at the preclinical and technology-development stage, with emphasis on targeted delivery, next-generation cell therapy enablement, and GMP process development.